Details of the Drug

General Information of Drug (ID: DMSVOCZ)

Drug Name

Pantoprazole

Synonyms

Astropan; Pantoprazol; Pantoprazolum; Pantoprozole; Pantor; Pantozol; Protium; Protonix; Somac; Pantoprazole Na; Pantoprazole Sodium; Protonix IV; BY 1023; Astropan (TN); BY-1023; Controloc (TN); Inipomp (TN); Pantecta (TN); Pantoloc (TN); Pantopan (TN); Pantoprazol [INN-Spanish]; Pantoprazolum [INN-Latin]; Pantor (TN); Pantotab (TN); Pantozol (TN); Protium (TN); Protonix (TN); SK&F 96022; SK-96022; SKF-96022; Somac (TN); Ulcepraz (TN); Pantoprazole (USAN/INN); Pantoprazole [USAN:BAN:INN]; SK&F-96022; 5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole

Indication

Disease Entry	ICD 11	Status	REF
Gastrinoma	2C10.1	Approved	[1]
Gastroesophageal reflux disease	DA22.Z	Approved	[2]
Peptic ulcer	DA61	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antiulcer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

383.4

Logarithm of the Partition Coefficient (xlogp)

2.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 5 mgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 2.5 mg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2-3 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 77% [3]
Clearance: The total clearance of drug is 7.6-14.0 L/h []
Elimination: After a single oral or intravenous (IV) dose of 14C-labeled pantoprazole to healthy, normal metabolizing subjects, about 71% of the dose was excreted in the urine, with 18% excreted in the feces by biliary excretion []
Half-life: The concentration or amount of drug in body reduced by one-half in 1 hours []
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.7398 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.02% [6]
Vd: The volume of distribution (Vd) of drug is 11.0-23.6 L []

Chemical Identifiers

Formula: C16H15F2N3O4S
IUPAC Name: 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole
Canonical SMILES: COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC
InChI: InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
InChIKey: IQPSEEYGBUAQFF-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4679
ChEBI ID: CHEBI:7915
CAS Number: 102625-70-7
DrugBank ID: DB00213
TTD ID: D0T6XX
VARIDT ID: DR00458
INTEDE ID: DR1236
ACDINA ID: D00508

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastric H(+)/K(+) ATPase (Proton pump)	TTLOKXP	ATP4A_HUMAN ; ATP4B_HUMAN	Modulator	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[8]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Mephenytoin 4-hydroxylase (CYP2C19)_{Main DME}	DEGTFWK	CP2CJ_HUMAN	Substrate	[11]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[12]
Sulfotransferase 1A1 (SULT1A1)	DEYWLRK	ST1A1_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Hepcidin (HAMP)	OT607RBL	HEPC_HUMAN	Gene/Protein Processing	[13]
Phospholipid-transporting ATPase ABCA1 (ABCA1)	OT94G6BQ	ABCA1_HUMAN	Gene/Protein Processing	[14]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Pantoprazole (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Cefuroxime	DMSIMD8	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Cefuroxime.	Acute bronchitis [CA42]	[15]
Framycetin	DMF8DNE	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Framycetin.	Alcoholic liver disease [DB94]	[16]
Paromomycin	DM1AGXN	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Paromomycin.	Amoebiasis [1A36]	[16]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Pantoprazole caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[17]
Posaconazole	DMUL5EW	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Posaconazole.	Aspergillosis [1F20]	[18]
Kanamycin	DM2DMPO	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Kanamycin.	Bacterial infection [1A00-1C4Z]	[16]
Amikacin	DM5PDRB	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Amikacin.	Bacterial infection [1A00-1C4Z]	[16]
Streptomycin	DME1LQN	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Streptomycin.	Bacterial infection [1A00-1C4Z]	[16]
Cefpodoxime	DMJUNY5	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Cefpodoxime.	Bacterial infection [1A00-1C4Z]	[15]
Gentamicin	DMKINJO	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Gentamicin.	Bacterial infection [1A00-1C4Z]	[16]
Capreomycin	DMNZBRY	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Capreomycin.	Bacterial infection [1A00-1C4Z]	[16]
Bacampicillin	DMP54C7	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Bacampicillin.	Bacterial infection [1A00-1C4Z]	[15]
Netilmicin	DMRD1QK	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Netilmicin.	Bacterial infection [1A00-1C4Z]	[16]
Cefditoren	DMSUVM1	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Cefditoren.	Bacterial infection [1A00-1C4Z]	[19]
Tobramycin	DMUI0CH	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Tobramycin.	Bacterial infection [1A00-1C4Z]	[16]
Vismodegib	DM5IXKQ	Minor	Decreased absorption of Pantoprazole due to altered gastric pH caused by Vismodegib.	Basal cell carcinoma [2C32]	[20]
Pexidartinib	DMS2J0Z	Major	Decreased absorption of Pantoprazole due to altered gastric pH caused by Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[21]
HKI-272	DM6QOVN	Major	Decreased absorption of Pantoprazole due to altered gastric pH caused by HKI-272.	Breast cancer [2C60-2C6Y]	[20]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Pantoprazole caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[22]
Bosutinib	DMTI8YE	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Bosutinib.	Breast cancer [2C60-2C6Y]	[23]
Atorvastatin	DMF28YC	Moderate	Increased plasma concentrations of Pantoprazole and Atorvastatin due to competitive inhibition of the same metabolic pathway.	Cardiovascular disease [BA00-BE2Z]	[24]
Anisindione	DM2C48U	Moderate	Decreased metabolism of Pantoprazole caused by Anisindione mediated inhibition of CYP450 enzyme.	Coagulation defect [3B10]	[25]
Panitumumab	DMQPD1F	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Panitumumab.	Colorectal cancer [2B91]	[16]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Pantoprazole caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[26]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Pantoprazole caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[27]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Pantoprazole caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[28]
Duloxetine	DM9BI7M	Minor	Decreased absorption of Pantoprazole due to altered gastric pH caused by Duloxetine.	Depression [6A70-6A7Z]	[29]
Oxcarbazepine	DM5PU6O	Moderate	Decreased metabolism of Pantoprazole caused by Oxcarbazepine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[20]
Cenobamate	DM8KLU9	Moderate	Decreased metabolism of Pantoprazole caused by Cenobamate mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[30]
Brivaracetam	DMSEPK8	Minor	Decreased metabolism of Pantoprazole caused by Brivaracetam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[31]
Ethacrynic acid	DM60QMR	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Ethacrynic acid.	Essential hypertension [BA00]	[32]
Bendroflumethiazide	DM7EVLC	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Bendroflumethiazide.	Essential hypertension [BA00]	[16]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Benzthiazide.	Essential hypertension [BA00]	[16]
Itraconazole	DMCR1MV	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Itraconazole.	Fungal infection [1F29-1F2F]	[33]
Pentamidine	DMHZJCG	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Pentamidine.	Fungal infection [1F29-1F2F]	[16]
Ketoconazole	DMPZI3Q	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Ketoconazole.	Fungal infection [1F29-1F2F]	[33]
Amphotericin B	DMTAJQE	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Amphotericin B.	Fungal infection [1F29-1F2F]	[16]
Chlorothiazide	DMLHESP	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Chlorothiazide.	Heart failure [BD10-BD1Z]	[16]
Furosemide	DMMQ8ZG	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Furosemide.	Heart failure [BD10-BD1Z]	[16]
Digoxin	DMQCTIH	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Digoxin.	Heart failure [BD10-BD1Z]	[34]
Bumetanide	DMRV7H0	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Bumetanide.	Heart failure [BD10-BD1Z]	[16]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[16]
Torasemide	DMXKJ6C	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Torasemide.	Heart failure [BD10-BD1Z]	[32]
GS-5885	DMSL3DX	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by GS-5885.	Hepatitis virus infection [1E50-1E51]	[20]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Pantoprazole caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[31]
Indinavir	DM0T3YH	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Indinavir.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Delavirdine	DM3NF5G	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Delavirdine.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Fosamprenavir	DM4W9B3	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Fosamprenavir.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Pantoprazole caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Rilpivirine	DMJ0QOW	Major	Decreased absorption of Pantoprazole due to altered gastric pH caused by Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Atazanavir	DMSYRBX	Major	Decreased absorption of Pantoprazole due to altered gastric pH caused by Atazanavir.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Raltegravir	DMYURI6	Minor	Decreased absorption of Pantoprazole due to altered gastric pH caused by Raltegravir.	Human immunodeficiency virus disease [1C60-1C62]	[41]
Simvastatin	DM30SGU	Moderate	Decreased clearance of Pantoprazole and Simvastatin due to competitive inhibition of the same transporter.	Hyper-lipoproteinaemia [5C80]	[24]
Lovastatin	DM9OZWQ	Moderate	Increased plasma concentrations of Pantoprazole and Lovastatin due to competitive inhibition of the same metabolic pathway.	Hyper-lipoproteinaemia [5C80]	[24]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Pantoprazole caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[20]
Indapamide	DMGN1PW	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Indapamide.	Hypertension [BA00-BA04]	[16]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Trichlormethiazide.	Hypertension [BA00-BA04]	[16]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[16]
Liothyronine	DM6IR3P	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Liothyronine.	Hypo-thyroidism [5A00]	[20]
Levothyroxine	DMHN027	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Levothyroxine.	Hypo-thyroidism [5A00]	[20]
Iron	DMAP8MV	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Iron.	Iron deficiency anaemia [3A00]	[42]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Pantoprazole caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[31]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Pantoprazole and Porfimer Sodium.	Lung cancer [2C25]	[43]
Ceritinib	DMB920Z	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Ceritinib.	Lung cancer [2C25]	[44]
Erlotinib	DMCMBHA	Major	Decreased absorption of Pantoprazole due to altered gastric pH caused by Erlotinib.	Lung cancer [2C25]	[20]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Pantoprazole caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[20]
Dacomitinib	DMOH8VY	Major	Decreased absorption of Pantoprazole due to altered gastric pH caused by Dacomitinib.	Lung cancer [2C25]	[31]
Selpercatinib	DMZR15V	Major	Decreased absorption of Pantoprazole due to altered gastric pH caused by Selpercatinib.	Lung cancer [2C25]	[31]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Pantoprazole caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[45]
Acalabrutinib	DM7GCVW	Major	Decreased absorption of Pantoprazole due to altered gastric pH caused by Acalabrutinib.	Mature B-cell lymphoma [2A85]	[46]
Ponatinib	DMYGJQO	Minor	Decreased absorption of Pantoprazole due to altered gastric pH caused by Ponatinib.	Mature B-cell lymphoma [2A85]	[20]
Flibanserin	DM70DTN	Moderate	Decreased metabolism of Pantoprazole caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[47]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Pantoprazole caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[31]
Nilotinib	DM7HXWT	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Nilotinib.	Myeloproliferative neoplasm [2A20]	[48]
Dasatinib	DMJV2EK	Major	Decreased absorption of Pantoprazole due to altered gastric pH caused by Dasatinib.	Myeloproliferative neoplasm [2A20]	[49]
Prasugrel	DM7MT6E	Minor	Decreased absorption of Pantoprazole due to altered gastric pH caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[50]
Modafinil	DMYILBE	Moderate	Decreased metabolism of Pantoprazole caused by Modafinil mediated inhibition of CYP450 enzyme.	Narcolepsy [7A20]	[20]
Chlorthalidone	DM4DMBT	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Chlorthalidone.	Oedema [MG29]	[16]
Metolazone	DMB39LO	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Metolazone.	Oedema [MG29]	[16]
Polythiazide	DMCH80F	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Polythiazide.	Oedema [MG29]	[16]
Naproxen	DMZ5RGV	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Naproxen.	Osteoarthritis [FA00-FA05]	[51]
Carboplatin	DMG281S	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Carboplatin.	Ovarian cancer [2C73]	[16]
Aspirin	DM672AH	Minor	Decreased absorption of Pantoprazole due to altered gastric pH caused by Aspirin.	Pain [MG30-MG3Z]	[52]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Pantoprazole caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[53]
Choline salicylate	DM8P137	Minor	Decreased absorption of Pantoprazole due to altered gastric pH caused by Choline salicylate.	Postoperative inflammation [1A00-CA43]	[52]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Pantoprazole caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[54]
Enzalutamide	DMGL19D	Moderate	Accelerated clearance of Pantoprazole due to the transporter induction by Enzalutamide.	Prostate cancer [2C82]	[55]
Riociguat	DMXBLMP	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Riociguat.	Pulmonary hypertension [BB01]	[56]
Axitinib	DMGVH6N	Minor	Decreased absorption of Pantoprazole due to altered gastric pH caused by Axitinib.	Renal cell carcinoma [2C90]	[57]
Salsalate	DM13P4C	Minor	Decreased absorption of Pantoprazole due to altered gastric pH caused by Salsalate.	Rheumatoid arthritis [FA20]	[52]
Salicyclic acid	DM2F8XZ	Minor	Decreased absorption of Pantoprazole due to altered gastric pH caused by Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[52]
Gefitinib	DM15F0X	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Gefitinib.	Solid tumour/cancer [2A00-2F9Z]	[58]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Pantoprazole caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
Armodafinil	DMGB035	Moderate	Decreased metabolism of Pantoprazole caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
Cisplatin	DMRHGI9	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Cisplatin.	Solid tumour/cancer [2A00-2F9Z]	[16]
Vandetanib	DMRICNP	Minor	Decreased absorption of Pantoprazole due to altered gastric pH caused by Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[20]
Warfarin	DMJYCVW	Moderate	Decreased metabolism of Pantoprazole caused by Warfarin mediated inhibition of CYP450 enzyme.	Supraventricular tachyarrhythmia [BC81]	[25]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Pantoprazole due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[59]
Dicumarol	DMFQCB1	Moderate	Decreased metabolism of Pantoprazole caused by Dicumarol mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[60]
Clopidogrel	DMOL54H	Moderate	Decreased metabolism of Pantoprazole caused by Clopidogrel mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[61]
Mycophenolate mofetil	DMPQAGE	Moderate	Decreased absorption of Pantoprazole due to altered gastric pH caused by Mycophenolate mofetil.	Transplant rejection [NE84]	[62]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Tacrolimus.	Transplant rejection [NE84]	[20]
Plazomicin	DMKMBES	Moderate	Increased risk of hypomagnesemia by the combination of Pantoprazole and Plazomicin.	Urinary tract infection [GC08]	[16]
-----------


⏷ Show the Full List of 103 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Calcium carbonate	E00198	10112	Binding agent; Buffering agent; Diluent; Opacifying agent
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Calcium stearate	E00244	15324	lubricant
Carbonic acid disodium salt	E00199	10340	Alkalizing agent; Buffering agent; Diluent; Dispersing agent
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Glyceryl behenate	E00481	5362585	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Glyceryl dibehenate	E00537	22477175	Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Isobutyl alcohol	E00130	6560	Flavoring agent; Solvent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Propylene glycol distearate	E00395	110800	Emollient; Opacifying agent; Surfactant
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium carbonate decahydrate	E00405	151402	Alkalizing agent; Buffering agent; Diluent; Dispersing agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 39 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Pantoprazole 20 mg tablet	20 mg	Delayed Release Oral Tablet	Oral
Pantoprazole 40 mg tablet	40 mg	Delayed Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Pantoprazole FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7260).
3	Bardou M, Martin J: Pantoprazole: from drug metabolism to clinical relevance. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):471-83. doi: 10.1517/17425255.4.4.471 .
4	BDDCS applied to over 900 drugs
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11.
9	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
10	Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med. 1996 May-Jun;69(3):203-9.
11	Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):447-460.
12	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13	Proton pump inhibitors block iron absorption through direct regulation of hepcidin via the aryl hydrocarbon receptor-mediated pathway. Toxicol Lett. 2020 Jan;318:86-91. doi: 10.1016/j.toxlet.2019.10.016. Epub 2019 Oct 24.
14	Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist. Biochem Pharmacol. 2010 May 1;79(9):1310-6. doi: 10.1016/j.bcp.2009.12.018. Epub 2010 Jan 8.
15	Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
16	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
17	Eiden C, Peyriere H, Tichit R, et al. "Inherited long QT syndrome revealed by antifungals drug-drug interaction." J Clin Pharm Ther 32 (2007): 321-4. [PMID: 17489884]
18	Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
19	Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
20	Cerner Multum, Inc. "Australian Product Information.".
21	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
22	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
23	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
24	Bogman K, Peyer AK, Torok M, Kusters E, Drewe J "HMG-CoA reductase inhibitors and P-glycoprotein modulation." Br J Pharmacol 132 (2001): 1183-92. [PMID: 11250868]
25	Ahmad S "Omeprazole-warfarin interaction." South Med J 84 (1991): 674-5. [PMID: 2035104]
26	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
27	Cerner Multum, Inc. "Canadian Product Information.".
28	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
29	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
30	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
31	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
32	Product Information. Nexium (esomeprazole) Astra-Zeneca Pharmaceuticals, Wilmington, DE.
33	Bottiger Y, Tybring G, Gotharson E, Bertilsson L "Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin." Clin Pharmacol Ther 62 (1997): 384-91. [PMID: 9357389]
34	Andersson T "Omeprazole drug interaction studies." Clin Pharmacokinet 21 (1991): 195-212. [PMID: 1764870]
35	Burger DM, Hugen PWH, Kroon FP, Groeneveld P, Brinkman K, Foudraine NA, Sprenger H, Koopmans PP, Hekster YA "Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir." AIDS 12 (1998): 2080-2. [PMID: 9814882]
36	Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
37	Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
38	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
39	Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
40	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
41	Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
42	Hutchison C, Geissler CA, Powell JJ, Bomford A "Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis." Gut 56 (2007): 1291-5. [PMID: 17344278]
43	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
44	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
45	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
46	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
47	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
48	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
49	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
50	Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
51	Product Information. Naprosyn (naproxen). Syntex Laboratories Inc, Palo Alto, CA.
52	Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
53	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
54	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
55	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
56	Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
57	Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
58	Product Information. Iressa (gefitinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
59	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
60	Product Information. Omeprazole (omeprazole). Mylan Pharmaceuticals Inc, Morgantown, WV.
61	Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
62	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.